Avitide develops customized biopharmaceutical affinity purification products. The Avitide platform reduces bioprocess development timelines, program risk, and cost of manufacture by providing turnkey, cost-effective, highly specific affinity purification solutions. Industry-leading affinity resin discovery timelines integrate seamlessly into process development cycles, providing improved line-of-sight, platform operations and equipment, and predictable scalability.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/15/13 | undisclosed | Series A |
Angeli Parvi Borealis Ventures OrbiMed Advisors Polaris Partners | undisclosed |
| 03/15/13 | undisclosed | Series A | ||
| 08/06/15 | undisclosed | Series C |
Borealis Ventures NeoMed Management OrbiMed Advisors Polaris Partners | undisclosed |
